Jafron Biomedical Co Ltd
SZSE:300529
Intrinsic Value
Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. [ Read More ]
The intrinsic value of one Jafron Biomedical Co Ltd stock under the Base Case scenario is 24.62 CNY. Compared to the current market price of 26.15 CNY, Jafron Biomedical Co Ltd is Overvalued by 6%.
Valuation Backtest
Jafron Biomedical Co Ltd
Run backtest to discover the historical profit from buying and selling Jafron Biomedical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Jafron Biomedical Co Ltd
| Current Assets | 3.3B |
| Cash & Short-Term Investments | 2.7B |
| Receivables | 168.9m |
| Other Current Assets | 463.8m |
| Non-Current Assets | 2.2B |
| Long-Term Investments | 69.4m |
| PP&E | 1.7B |
| Intangibles | 137.1m |
| Other Non-Current Assets | 206.3m |
| Current Liabilities | 819.5m |
| Accounts Payable | 60.6m |
| Accrued Liabilities | 32.2m |
| Short-Term Debt | 412.8m |
| Other Current Liabilities | 313.9m |
| Non-Current Liabilities | 1.6B |
| Long-Term Debt | 1.4B |
| Other Non-Current Liabilities | 166.8m |
Earnings Waterfall
Jafron Biomedical Co Ltd
|
Revenue
|
2B
CNY
|
|
Cost of Revenue
|
-419.1m
CNY
|
|
Gross Profit
|
1.5B
CNY
|
|
Operating Expenses
|
-1B
CNY
|
|
Operating Income
|
495.3m
CNY
|
|
Other Expenses
|
-55.5m
CNY
|
|
Net Income
|
439.7m
CNY
|
Free Cash Flow Analysis
Jafron Biomedical Co Ltd
Profitability Score
Profitability Due Diligence
Jafron Biomedical Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Jafron Biomedical Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Jafron Biomedical Co Ltd's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Jafron Biomedical Co Ltd's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Jafron Biomedical Co Ltd
According to Wall Street analysts, the average 1-year price target for Jafron Biomedical Co Ltd is 27.15 CNY with a low forecast of 25.48 CNY and a high forecast of 29.4 CNY.
Shareholder Return
Price
Jafron Biomedical Co Ltd
| Average Annual Return | 11.83% |
| Standard Deviation of Annual Returns | 60.91% |
| Max Drawdown | -83% |
| Market Capitalization | 20.6B CNY |
| Shares Outstanding | 807 711 312 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.
Contact
IPO
Employees
Officers
The intrinsic value of one Jafron Biomedical Co Ltd stock under the Base Case scenario is 24.62 CNY.
Compared to the current market price of 26.15 CNY, Jafron Biomedical Co Ltd is Overvalued by 6%.
You don't have any saved screeners yet
